16 June 2016 - NICE has published an appraisal consultation for Roche's cobimetinib hemifumarate (Cotellic).

Cobimetinib hemifumarate, when used in combination with vemurafenib, is not recommended within its marketing authorisation for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.

The closing date for comments is 7 July 2016; they will be considerad at the second appraisal committee meeting on 19 July 2016.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/GID-TAG523/consultation/html-content